Volume 11, Issue 1 (2025)
Pharm Biomed Res 2025, 11(1): 75-80 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Asadi A, Salehi M, Setareh J. Unusual Weight Loss in a Schizophrenic Patient Following Treatment With Aripiprazole: A Case Report. Pharm Biomed Res 2025; 11 (1) :75-80
URL: http://pbr.mazums.ac.ir/article-1-665-en.html
URL: http://pbr.mazums.ac.ir/article-1-665-en.html
1- Department of Psychiatry, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. & Psychiatry and Behavioral Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran.
2- Student Research Committee, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
2- Student Research Committee, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Abstract: (284 Views)
Background: The main problem with second-generation antipsychotic (SGAs) drugs is weight gain. It was shown that aripiprazole can induce mild weight loss in some patients.
Case Report: In this study, we present a 32-year-old man with schizophrenia who, before initiating aripiprazole, had been treated with clozapine (standard oral tablets) at a daily dosage of 300 mg. During 9 years of clozapine therapy, the patient experienced substantial weight gain, totaling 51 kg, which increased his weight to 145 kg. Concurrently, he displayed limited interest in social interactions, remained primarily confined to his home watching television, and was unemployed. At the time of hospitalization, clozapine treatment was discontinued, and aripiprazole was introduced with the patient weighing 145 kg. Over the subsequent 60 days of aripiprazole treatment, the patient demonstrated a significant weight loss of 28 kg, a reduction that was both remarkable and clinically significant.
Conclusion: Switching from clozapine to aripiprazole led to significant weight loss in a patient with schizophrenia, highlighting aripiprazole’s potential in managing antipsychotic-induced weight gain.
Case Report: In this study, we present a 32-year-old man with schizophrenia who, before initiating aripiprazole, had been treated with clozapine (standard oral tablets) at a daily dosage of 300 mg. During 9 years of clozapine therapy, the patient experienced substantial weight gain, totaling 51 kg, which increased his weight to 145 kg. Concurrently, he displayed limited interest in social interactions, remained primarily confined to his home watching television, and was unemployed. At the time of hospitalization, clozapine treatment was discontinued, and aripiprazole was introduced with the patient weighing 145 kg. Over the subsequent 60 days of aripiprazole treatment, the patient demonstrated a significant weight loss of 28 kg, a reduction that was both remarkable and clinically significant.
Conclusion: Switching from clozapine to aripiprazole led to significant weight loss in a patient with schizophrenia, highlighting aripiprazole’s potential in managing antipsychotic-induced weight gain.
Keywords: Schizophrenia, Antipsychotic agents, Clozapine, Aripiprazole, Weight loss, Body mass index (BMI), Weight gain
Type of Study: case report |
Subject:
Clinical Pharmacy
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
